![]() ![]() Studying anti-dsDNA antibodies present in SLE patients and in animal models of lupus, we have identified a subset of anti-dsDNA antibodies which is pathogenic in the brain as well as in the kidney. Many anti-dsDNA antibodies cross-react with non-DNA antigens that may be the direct targets for their pathogenic activity. The major auto-specificity in SLE is double-stranded (ds) DNA. Thus, the current therapies for SLE are based on the concept of nonspecific immunosuppression and consist of nonsteroidal anti-inflammatory drugs (NSAIDS), corticosteroids, anti-malarials and cytotoxic drugs, all of which have serious adverse side effects including organ damage. The underlying aetiology of SLE autoantibodies remains unknown, and treatments aimed at eliminating B cells, or limiting their function, have demonstrated limited therapeutic benefit. ![]() Systemic lupus erythematosus (SLE) is characterized by the presence of autoantibodies that can mediate tissue damage in multiple organs. Diamond B, Bloom O, Al Abed Y, Kowal C, Huerta PT, Volpe BT (Autoimmune & Musculoskeletal Disease Center, The Feinstein Institute for Medical Research, Manhasset and Department of Neurology & Neuroscience, Burke Cornell Medical Research Institute, Weill Medical College of Cornell University, White Plains, NY, USA) Moving towards a cure: blocking pathogenic antibodies in systemic lupus erythematosus (Key Symposium).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |